New early warning system to prevent life-threatening urinary infections in catheter users

Infection alert in catheters could tackle hospital superbugs

Amsterdam ( April 25, 2016 ) – A new infection alert system in catheters could prevent serious infections in millions of hospital patients worldwide. The system, detailed in a new paper in Biosensors and Bioelectronics, changes the color of the urine so patients and carers can see easily if bacteria are st arting to block the catheter. The researchers who invented the new catheter infection alert, from the University of Bath, say it could help tackle these infections. It could also be beneficial for elderly people in care homes.

A catheter drains urine from the bladder when a person can’t release urine without help or is incontinent, including following anesthesia. 100 million urinary catheters are used around the world every year, but the infections they sometimes cause can be problematic for thousands of people. Hospital acquired urinary infections affect more than 90,000 patients a year in the US alone, according to the Centers for Disease Control and Prevention.

The new system designed by Dr. Toby Jenkins and his colleagues provides a means of early detection, so the catheter can be changed and the infection treated before a person becomes unwell.

"Catheter-related infections are a serious problem, especially if the bacteria are resistant to antibiotics. We hope that with this simple to use sensor system we can ultimately make a real difference to patients’ lives," said Dr. Jenkins.

Over time bacteria can build a layer called a biofilm inside the catheter tubes that eventually blocks them. The urine can’t escape and pushes back into the kidneys where the bacteria can cause kidney failure, body-wide infection and death. Up to half of people who use catheters long-term have problems with blockages caused by bacteria, but there is currently no way to detect potential blockages before they cause problems.

The new coating detects biofilms built by a bacterium called Proteus mirabilis, the most common cause of catheter blockage. The system gives advanced warning of a catheter blockage 10 to 12 hours before it happens.

The coating is made up of two layers. The first reacts to changes in urine caused by the bacteria, the second layer releases the dye. The dyed urine gathers in the collection bag, turning the urine bright yellow. The color change reveals the infection.

Dr. Jenkins’ team used a glass bladder, artificial urine and bacteria from patient samples to test the system. It responds to changes in the acidity, or pH, of urine caused by bacteria. As bacteria multiply, the substances they release raise the pH so the urine becomes more alkaline than acidic. This change dissolves the top layer of the coating, releasing the super-bright dye held in the second layer.

The glass bladder tests showed that when there is no bacterial infection the dye stays in the second layer despite liquid constantly flowing past it.

Biofilms built by bacteria are not easy to treat. They avoid the natural defenses of the immune system and can’t be broken down by antibiotics. Dr. Jenkins is optimistic about the benefits of the system: "Our new coating works with existing catheter designs and gives a clear, early visual warning of infection before a catheter is blocked. It could dramatically reduce the number of infections resulting from bacterial blockages."

The authors also hope the catheter coating could be used to cut the cost of treating infection, estimated to be £120million a year in England and Wales. The next step is to test the coating using urine collected from volunteers and then ultimately to run a clinical trial to show the system is safe and beneficial for patients.

Article details

The article is "An in-situ infection detection sensor coating for urinary catheters" by Scarlet Milo, Naing Tun, Thet, Dan Liu, Jonathan Nzakizwanayo, Brian V. Jones and A.Toby A. Jenkins (doi: 10.1016/j.bios.2016.02.059). It appears in Biosensors and Bioelectronics, Volume 81 (July 2016), published by Elsevier.

About Biosensors and Bioelectronics

Biosensors and Bioelectronics is the principal international journal devoted to research, design, development and application of biosensors and bioelectronics. It is an interdisciplinary journal serving professionals with an interest in the exploitation of biological materials and designs in novel diagnostic and electronic devices including sensors, DNA chips, electronic noses, lab-on-a-chip and μ-TAS.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey — and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries.

http://www.elsevier.com


Elsevier , 25.04.2016 (tB).

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 
Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…

ERNÄHRUNG

Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen

ONKOLOGIE

WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege

MULTIPLE SKLEROSE

Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…
Stellungnahme zur 3. Impfung gegen SARS-CoV2 bei Personen mit MS
NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…